FrancophonIA/ELRC3.0 huggingface dataset:
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Tarceva.
Croatian: Ako Vam je liječnik rekao da ne podnosite neke šećere, obratite mu se prije uzimanja lijeka Tarceva.
English: The primary metabolites OSI-420 and OSI-413 of erlotinib produced by O-demethylation of either side chain have comparable potency to erlotinib in non-clinical in vitro assays and in vivo tumour models.
Croatian: Osnovni metaboliti erlotiniba OSI-420 i OSI-413 dobiveni O-demetilacijom bilo kojeg postraničnog lanca imaju potenciju usporedivu s erlotinibom u nekliničkim analizama in vitro i tumorskim modelima in vivo.
English: As the potential for harm to the nursing infant is unknown, mothers should be advised against breast-feeding while receiving Tarceva and for at least 2 weeks after the final dose.
Croatian: Budući da potencijalna opasnost za dojenče nije poznata, majke je potrebno savjetovati da ne doje za vrijeme primjene lijeka Tarceva i još najmanje 2 tjedna nakon posljednje doze lijeka.
English: The objective of the study was to compare the overall survival of first line maintenance therapy with erlotinib versus erlotinib administered at the time of disease progression.
Croatian: Cilj ispitivanja bio je usporediti ukupno preživljenje (OS) uz erlotinib primijenjen u prvoj liniji terapije održavanja u odnosu na OS kod primjene erlotiniba u trenutku progresije bolesti.
English: The safety and efficacy of erlotinib has not been studied in patients with renal impairment (serum creatinine concentration >1.5 times the upper normal limit).
Croatian: Oštećenje bubrega Sigurnost i djelotvornost erlotiniba nije ispitana u bolesnika s oštećenjem bubrega (koncentracija serumskog kreatinina > 1,5 puta od gornje granice normale).
English: You are advised to stop smoking if you are treated with Tarceva as smoking could decrease the amount of your medicine in the blood.
Croatian: Ako se liječite lijekom Tarceva preporučuje se da prestanete pušiti jer pušenje može smanjiti razinu lijeka u krvi.
English: Dose reductions by 25 mg steps have not been investigated.
Croatian: Nisu ispitani slučajevi smanjenja doze za po 25 mg.
English: Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, and/or taxane based chemotherapy, or who have prior history of peptic ulceration or diverticular disease are at increased risk.
Croatian: Bolesnici koji istovremeno primaju antiangiogene lijekove, kortikosteroide, nesteroidne protuupalne lijekove, i/ili kemoterapiju baziranu na taksanima, ili oni koji u anamnezi imaju peptične ulceracije ili divertikuloznu bolest, imaju povećani rizik.
English: -Diarrhoea7 -Gastrointestinal bleeding4, 7
Croatian: - gastrointestinalno krvarenje 4, 7
English: When prescribing Tarceva, factors associated with prolonged survival should be taken into account (see sections 4.2 and 5.1).
Croatian: Prilikom propisivanja lijeka Tarceva treba uzeti u obzir faktore povezane s produljenim preživljenjem (vidjeti dio 4.2 i 5.1).
English: Hydroxypropyl cellulose (E463) Titanium dioxide (E171)
Croatian: Ovojnica tablete hidroksipropilceluloza (E463) titanijev dioksid (E171) makrogol hipromeloza (E464)
English: • if you use contact lenses and/or have a history of eye problems such as severe dry eyes, inflammation of the front part of the eye (cornea) or ulcers involving the front part of the eye, tell your doctor.
Croatian: · ako koristite kontaktne leće i/ili ste već imali tegobe s očima poput izuzetno suhih očiju, upale prednjega dijela oka (rožnice) odnosno ulceracije na prednjem dijelu oka, svakako o tome obavijestite svog liječnika.
English: The effects of concomitant administration of erlotinib with H2 antagonists and antacids are unknown; however, reduced bioavailability is likely.
Croatian: Učinci istovremene primjene erlotiniba s H2 antagonistima i antacidima nisu poznati, no vjerojatna je smanjena bioraspoloživost.
English: Single oral doses of Tarceva up to 1000 mg erlotinib in healthy subjects, and up to 1600 mg in cancer patients have been tolerated.
Croatian: Pojedinačna peroralna doza lijeka Tarceva do 1000 mg erlotiniba u zdravih osoba i do 1600 mg u bolesnika s rakom dobro se podnosi.
English: Your doctor may decide to permanently stop your treatment with Tarceva.
Croatian: Vaš će liječnik odlučiti treba li trajno prekinuti liječenje lijekom Tarceva.
English: A survival benefit of Tarceva was also observed in patients who did not achieve an objective tumour response (by RECIST).
Croatian: Prednost u preživljenju s lijekom Tarceva primijećena je također i u bolesnika koji nisu imali objektivan odgovor tumora (prema RECIST).
English: If you develop symptoms such as sudden difficulty in breathing associated with cough or fever contact your doctor immediately as you could suffer from this disease.
Croatian: Ako Vam se pojave simptomi kao što su iznenadne poteškoće s disanjem popraćene kašljem ili vrućicom, odmah se obratite liječniku jer možda patite od te bolesti.
English: If you stop taking Tarceva
Croatian: Ako prestanete uzimati lijek Tarceva
English: This was confirmed in a pharmacokinetic study in non-smoking and currently cigarette smoking healthy subjects receiving a single oral dose of 150 mg erlotinib.
Croatian: Ovo je potvrđeno u farmakokinetičkom ispitivanju u zdravih dobrovoljaca nepušača i pušača cigareta koji su primili jednokratnu dozu od 150 mg erlotiniba.
English: • If you have further questions, ask your doctor or pharmacist.
Croatian: · Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
English: Tarceva is available in strengths of 25 mg, 100 mg and 150 mg.
Croatian: Tarceva je dostupna u jačinama od 25 mg, 100 mg i 150 mg.
English: Patients with low expression levels of UGT1A1 or genetic glucuronidation disorders (e.g. Gilbert's disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.
Croatian: U bolesnika s niskim razinama ekspresije UGT1A1 ili genetičkim glukuronidacijskim bolestima (npr. Gilbertova bolest) može doći do povećane koncentracije bilirubina u serumu, pa je potreban oprez pri liječenju.
English: Tarceva is given in combination with gemcitabine treatment.
Croatian: Tarceva se daje u kombinaciji s terapijom gemcitabinom.
English: These findings were observed at exposures well below clinically relevant exposures.
Croatian: Ti su učinci opaženi pri izloženostima znatno nižima od klinički relevantnih izloženosti.
English: 67% of placebo patients in the EGFR mutation positive subgroup received second or further line treatment with EGFR-TKIs.
Croatian: Šezdeset i sedam posto (67%) bolesnika iz podskupine pozitivne na mutaciju EGFR-a koji su primali placebo primilo je i drugu ili daljnju liniju liječenja inhibitorima tirozin kinaze EGFR-a.
English: Safety evaluation of Tarceva is based on the data from more than 1500 patients treated with at least one 150 mg dose of Tarceva monotherapy and more than 300 patients who received Tarceva 100 or 150 mg in combination with gemcitabine.
Croatian: Ocjena sigurnosti lijeka Tarceva temelji se na podacima prikupljenima u više od 1500 bolesnika liječenih najmanje jednom dozom lijeka Tarceva od 150 mg u monoterapiji te više od 300 bolesnika koji su primali lijek Tarceva u dozi od 100 ili 150 mg u kombinaciji s gemcitabinom.
English: In the 45% of patients with known EGFR-expression status, the hazard ratio was 0.68 (95% CI 0.49-0.94) for patients with EGFR-positive tumours and 0.93 (95% CI 0.63-1.36) for patients with EGFR-negative tumours (defined by IHC using EGFR pharmDx kit and defining EGFR-negative as less than 10% tumour cells staining).
Croatian: U 45% bolesnika s poznatim statusom ekspresije EGFR, omjer rizika bio je 0,68 (95% CI 0,49-0,94) za bolesnike s EGFR pozitivnim tumorima i 0,93 (95% CI 0,63-1,36) za bolesnike s EGFR negativnim tumorima (definirano na temelju imunohistokemije pomoću EGFR pharmDx i definirano EGFR-negativno kao manje od 10% bojanja stanica tumora).
English: In another clinical study, erlotinib was shown not to affect pharmacokinetics of the concomitantly administered CYP3A4/2C8 substrate paclitaxel.
Croatian: U drugom kliničkom ispitivanju pokazalo se da erlotinib ne utječe na farmakokinetiku istovremeno primijenjenog CYP3A4/2C8 supstrata paklitaksela.
English: Based on the mode of action, erlotinib has the potential to be a teratogen.
Croatian: Erlotinib bi, na temelju djelovanja, mogao biti teratogen.
English: (Voir/siehe Belgique/Belgien)
Croatian: Luxembourg/Luxemburg (Voir/siehe Belgique/Belgien)
English: If adverse reactions related to erlotinib are observed, the dose of erlotinib may be reduced.
Croatian: Ako se primijete nuspojave vezane uz erlotinib, doza erlotiniba može se smanjiti.
English: Concomitant administration of inhibitors of Pgp, e.g. cyclosporine and verapamil, may lead to altered distribution and/or altered elimination of erlotinib.
Croatian: Pgp inhibitora, npr. ciklosporina i verapamila, može dovesti do promjene raspodjele i/ili uklanjanja erlotiniba.
English: Erlotinib and statins
Croatian: Erlotinib i statini
English: Some cases were secondary to severe dehydration due to diarrhoea, vomiting and/or anorexia, while others were confounded by concomitant chemotherapy.
Croatian: Do nekih je slučajeva došlo nakon teške dehidracije uslijed proljeva, povraćanja i/ili anoreksije, dok su neki uzroci nejasni zbog istovremenog primanja kemoterapije.
English: Manufacturer Roche Pharma AG Emil-Barell-Strasse 1
Croatian: Roche Pharma AG Emil-Barell-Strasse 1
English: Study endpoints included overall survival, progression-free survival (PFS), response rate, duration of response, time to deterioration of lung cancer-related symptoms (cough, dyspnoea and pain), and safety.
Croatian: Mjere ishoda ispitivanja uključivale su ukupno preživljenje, preživljenje bez pogoršanja bolesti (PFS), stopu odgovora, trajanje odgovora, vrijeme do pogoršanja simptoma vezanih uz rak pluća (kašalj, zaduha i bol) te sigurnost liječenja.
English: These studies were conducted in a total of 1532 patients with advanced, recurrent or metastatic NSCLC following first-line standard platinum-based chemotherapy, no new safety signals were identified.
Croatian: Ta su ispitivanja provedena u ukupno 1532 bolesnika s uznapredovalim, rekurentnim ili metastatskim NSCLC-om nakon prve linije standardne kemoterapije utemeljene na platini; nisu uočeni novi sigurnosni signali.
English: • if you are allergic to erlotinib or any of the ingredients of this medicine (listed in section 6).
Croatian: Nemojte uzimati lijek Tarceva · ako ste alergični na erlotinib ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
English: This effect was accompanied by a 24% increase in apparent erlotinib plasma clearance.
Croatian: Ovaj učinak praćen je 24%-tnim povećanjem prividnog klirensa erlotiniba u plazmi.
English: The BO25460 (IUNO) study was conducted in 643 patients with advanced NSCLC whose tumors did not harbor an EGFR-activating mutation (exon 19 deletion or exon 21 L858R mutation) and who had not experienced disease progression after four cycles of platinum-based chemotherapy.
Croatian: Ispitivanje BO25460 (IUNO) provedeno je u 643 bolesnika s uznapredovalim NSCLC-om čiji tumor nije imao aktivirajuću mutaciju EGFR-a (deleciju eksona 19 ili mutaciju L858R na eksonu 21) i koji nisu doživjeli progresiju bolesti nakon četiri ciklusa kemoterapije na bazi platine.
English: A mild phototoxic skin reaction was observed in rats after UV irradiation.
Croatian: U štakora je nakon UV zračenja primijećena blaga fototoksična reakcija na koži.
English: When erlotinib was given in combination with capecitabine, there was a statistically significant increase in erlotinib AUC and a borderline increase in Cmax when compared with values observed in another study in which erlotinib was given as single agent.
Croatian: Kada je erlotinib davan u kombinaciji s kapecitabinom, došlo je do statistički značajnog povećanja AUCa erlotiniba i granično značajnog povećanja vrijednosti Cmax u usporedbi s vrijednostima uočenima u drugom ispitivanju u kojem je erlotinib davan sam.
English: Current smokers should be advised to stop smoking, as plasma concentrations of erlotinib in smokers as compared to non-smokers are reduced.
Croatian: Pušačima treba savjetovati da prestanu pušiti jer je ustanovljeno da je koncentracija erlotiniba u plazmi pušača značajno manja u usporedbi s koncentracijom u nepušača.
English: Two-year carcinogenicity studies with erlotinib conducted in rats and mice were negative up to exposures exceeding human therapeutic exposure (up to 2-fold and 10-fold higher, respectively, based on Cmax and/or AUC).
Croatian: Dvogodišnja ispitivanja karcinogenosti erlotiniba provedena na štakorima i miševima čije su izloženosti prelazile terapijske izloženosti kod ljudi (do 2 puta odnosno 10 puta više, temeljeno na Cmax i/ili AUC) dala su negativan rezultat.
English: The recommended daily dose of Tarceva is 150 mg taken at least one hour before or two hours after the ingestion of food.
Croatian: Preporučena dnevna doza lijeka Tarceva iznosi 150 mg, a uzima se najmanje sat vremena prije ili dva sata nakon obroka.
English: When prescribing Tarceva, factors associated with prolonged survival should be taken into account.
Croatian: Prilikom propisivanja lijeka Tarceva treba uzeti u obzir faktore povezane s produljenim preživljenjem.
English: Capecitabine may increase erlotinib concentrations.
Croatian: Kapecitabin može povećati koncentracije erlotiniba.
English: Erlotinib and other CYP substrates
Croatian: Erlotinib i ostali CYP supstrati
English: In patients who develop acute onset of new and/or progressive unexplained pulmonary symptoms such as dyspnoea, cough and fever, Tarceva therapy should be interrupted pending diagnostic evaluation.
Croatian: U bolesnika koji razviju akutne nove i/ili progresivne neobjašnjene plućne simptome, poput zaduhe, kašlja ili vrućice, potrebno je obustaviti terapiju lijekom Tarceva dok se ne učini dijagnostička obrada.
English: In a double-blind, randomised phase III study (MO22162, CURRENTS) comparing two doses of Tarceva (300 mg versus 150 mg) in current smokers (mean of 38 pack years) with locally advanced or metastatic NSCLC in the second-line setting after failure on chemotherapy, the 300 mg dose of Tarceva demonstrated no PFS benefit over the recommended dose (7.00 vs 6.86 weeks, respectively).
Croatian: U dvostruko slijepom, randomiziranom ispitivanju faze III (MO22162, CURRENTS), u kojem su se uspoređivale dvije doze lijeka Tarceva (300 mg naspram 150 mg) u bolesnika pušača (srednja vrijednost 38 kutija-godina) s lokalno uznapredovalim ili metastatskim NSCLC-om u drugoj liniji liječenja nakon neuspješne kemoterapije, doza lijeka Tarceva od 300 mg nije ostvarila dodatne korisne učinke na PFS u odnosu na preporučenu dozu (7,00 naspram 6,86 tjedana).
English: In patients with solid tumours and with moderately impaired hepatic function (Child-Pugh score 7-9), geometric mean erlotinib AUC0-t and Cmax was 27000 ng•h/mL and 805 ng/mL, respectively, as compared to 29300 ng•h/mL and 1090 ng/mL in patients with adequate hepatic function including patients with primary liver cancer or hepatic metastases.
Croatian: U bolesnika sa solidnim tumorima i umjerenim oštećenjem funkcije jetre (Child-Pugh indeks 7 - 9) geometrijska sredina AUC0-t erlotiniba iznosila je 27 000 ng•h/ml, a Cmax 805 ng/ml u usporedbi s 29 300 ng•h/ml odnosno 1090 ng/ml u bolesnika s odgovarajućom funkcijom jetre, uključujući bolesnike s primarnim rakom jetre ili metastazama u jetri.
English: The primary active metabolites were present in tumour at concentrations averaging 160 ng/g tissue, which corresponded to an overall average of 113% (range 88-130%) of the observed steady state peak plasma concentrations.
Croatian: Primarni aktivni metaboliti u tumoru bili su prisutni u koncentracijama od oko 160 ng/g tkiva, što je odgovaralo ukupnom prosjeku od 113% (u rasponu od 88 do 130%) opaženih vršnih koncentracija u plazmi u stanju dinamičke ravnoteže.
English: Patients presenting with signs and symptoms suggestive of keratitis such as acute or worsening: eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red eye should be referred promptly to an ophthalmology specialist.
Croatian: Bolesnike sa znakovima i simptomima koji ukazuju na keratitis, poput akutne ili pogoršanja postojeće: upale oka, suzenja, osjetljivosti na svjetlost, zamućenoga vida, boli u oku i/ili crvenila oka, treba odmah uputiti specijalistu oftalmologu.
English: You may have increased side effects and your doctor may interrupt your treatment.
Croatian: Nuspojave se mogu pojačati, pa će Vam liječnik možda zaustaviti liječenje.
English: In a meta-analysis of NSCLC randomised controlled clinical trials (excluding phase I and single-arm phase II studies due to lack of control groups), the incidence of ILD-like events was 0.9% on Tarceva compared to 0.4% in patients in the control arms.
Croatian: U meta-analizi randomiziranih kontroliranih kliničkih ispitivanja kod NSCLC-a (isključujući ispitivanja faze I i ispitivanja faze II s jednom skupinom jer nije bilo kontrolne skupine), incidencija događaja nalik IBP-u iznosila je 0,9% uz lijek Tarceva, u usporedbi s 0,4% u bolesnika u kontrolnim skupinama.
English: Combination of erlotinib with proton pump inhibitors should be avoided.
Croatian: Treba izbjegavati kombinaciju erlotiniba i inhibitora protonske pumpe.
English: Table 3: Efficacy results of Tarceva versus chemotherapy in trial ML20650 (EURTAC)
Croatian: Tablica 3: Rezultati djelotvornosti lijeka Tarceva naspram kemoterapiji u ispitivanju ML20650 (EURTAC)
English: Do not breast-feed if you are being treated with Tarceva, and for at least 2 weeks after taking the last tablet.
Croatian: Ne dojite dijete dok se liječite lijekom Tarceva i još najmanje 2 tjedna nakon što uzmete posljednju tabletu.
English: Dose modifications (interruptions or reductions) for rash and diarrhoea were needed in 11% and 7% of patients, respectively.
Croatian: Prilagodbe doze (privremeni prekid primjene ili smanjenje doze) zbog osipa i proljeva bile su potrebne u 11% odnosno 7% bolesnika.
English: Patients who never smoked had a much greater benefit from erlotinib (survival HR = 0.42, 95% CI 0.28-0.64) compared with current or ex-smokers (HR = 0.87, 95% CI 0.71-1.05).
Croatian: Bolesnici koji nikada nisu pušili imali su veću korist od erlotiniba (preživljenje HR = 0,42; 95% CI 0,28-0,64) u usporedbi s onima koji puše ili su pušili (HR = 0,87; 95% CI 0,71-1,05).
English: Erlotinib and medicinal products altering pH
Croatian: Erlotinib i lijekovi koji mijenjaju pH vrijednost
English: -Palmar plantar erythrodysaesthesia syndrome
Croatian: - sindrom palmarnoplantarne eritrodizestezije
English: However, smokers had an increased rate of erlotinib clearance.
Croatian: Međutim, pušači su imali povećanu brzinu klirensa erlotiniba.
English: Tarceva dosing should be interrupted if changes in liver function are severe (see section 4.8).
Croatian: Uzimanje lijeka Tarceva valja prekinuti ako su promjene funkcije jetre teške (vidjeti dio 4.8).
English: Dose modifications (interruptions or reductions) for rash and diarrhoea were needed in 8.3% and 3% of patients, respectively, in study BO18192 and 5.6% and 2.8% of patients, respectively, in study BO25460.
Croatian: Prilagodbe doze (privremeni prekid primjene ili smanjenje doze) zbog osipa i proljeva bile su potrebne u 8,3% odnosno 3% bolesnika u ispitivanju BO18192 te u 5,6% odnosno 2,8% bolesnika u ispitivanju BO25460.
English: Rare cases of hepatic failure (including fatalities) have been reported during use of Tarceva.
Croatian: Postoje izvještaji o rijetkim slučajevima zatajenja jetre (uključujući smrtne slučajeve) tijekom uzimanja lijeka Tarceva.
English: If the use of antacids is considered necessary during treatment with Tarceva, they should be taken at least 4 hours before or 2 hours after the daily dose of Tarceva.
Croatian: Ako je primjena antacida nužna tijekom terapije lijekom Tarceva, treba ih uzimati barem 4 sata prije odnosno 2 sata nakon dnevne doze lijeka Tarceva.
English: Patients with bullous and exfoliative skin disorders should be tested for skin infection and treated according to local management guidelines.
Croatian: Bolesnike s buloznim ili eksfolijativnim promjenama na koži treba testirati na kožne infekcije i liječiti u skladu s loklanim smjernicama.
English: Tarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.
Croatian: Tarceva je u kombinaciji s gemcitabinom indicirana za liječenje bolesnika s metastatskim rakom gušterače.
English: There have been rare reports of hypokalaemia and renal failure (including fatalities).
Croatian: Zabilježeni su rijetki slučajevi hipokalemije i zatajenja bubrega (uključujući smrtne ishode).
English: The efficacy of Tarceva in first-line treatment of patients with EGFR activating mutations in NSCLC was demonstrated in a phase III, randomised, open-label trial (ML20650, EURTAC).
Croatian: Djelotvornost lijeka Tarceva u prvoj liniji liječenja bolesnika s EGFR aktivirajućim mutacijama u NSCLC-u potvrđena je u randomiziranom, otvorenom ispitivanju faze III (ML20650, EURTAC).
English: Studies in animals have shown no evidence of impaired fertility.
Croatian: Plodnost Ispitivanja na životinjama nisu pokazala znakove smanjenja plodnosti.
English: In a post-hoc analysis, patients on Tarceva who developed a rash had a longer overall survival compared to patients who did not develop rash (median OS 7.2 months vs 5 months, HR:0.61).
Croatian: Post hoc analiza također je pokazala da su bolesnici koji su primali lijek Tarceva i u kojih se pojavio osip imali dulje ukupno preživljenje u usporedbi s bolesnicima u kojih se nije razvio osip (medijan ukupnog preživljenja 7,2 mjeseca naspram 5 mjeseci, HR:0,61).
English: • Severe blistering or peeling of skin (suggestive of Stevens-Johnson syndrome)
Croatian: · vrlo izraženo stvaranje mjehura na koži ili ljuštenja kože (ukazuje na Stevens-Johnsonov sindrom) · upala obojenog dijela oka
English: Tablet core: lactose monohydrate, cellulose microcrystalline, sodium starch glycolate type A, sodium laurilsulfate, magnesium stearate (see also section 2 for lactose monohydrate).
Croatian: Jezgra tablete: laktoza hidrat, mikrokristalična celuloza, natrijev škroboglikolat vrste A, natrijev laurilsulfat, magnezijev stearat (pogledajte također dio 2 vezano uz laktozu hidrat).
English: Tarceva is a medicine used to treat cancer by preventing the activity of a protein called epidermal growth factor receptor (EGFR).
Croatian: Tarceva je lijek namijenjen liječenjuraka pluća nemalih stanica koji djeluje tako što sprječava aktivnost proteina zvanog receptor epidermalnog faktora rasta (EGFR).
English: When considering the use of Tarceva as a first line or maintenance treatment for locally advanced or metastatic NSCLC, it is important that the EGFR mutation status of a patient is determined.
Croatian: Kada se razmatra primjena lijeka Tarceva kao prve linije liječenja ili terapije održavanja za lokalno uznapredovali ili metastatski NSCLC važno je odrediti status EGFR mutacije.
English: Although erlotinib exposure was similar in patients with moderately impaired hepatic function (Child-Pugh score 7-9) compared with patients with adequate hepatic function, caution should be used when administering Tarceva to patients with hepatic impairment.
Croatian: Iako je izloženost erlotinibu u bolesnika s umjerenim oštećenjem funkcije jetre (Child-Pugh indeks 7 - 9) bila slična onoj u bolesnika s odgovarajućom funkcijom jetre, potreban je oprez kod primjene lijeka Tarceva u bolesnika s oštećenjem jetre.
English: A second population pharmacokinetic analysis was conducted that incorporated erlotinib data from 204 pancreatic cancer patients who received erlotinib plus gemcitabine.
Croatian: Provedena je druga populacijska farmakokinetička analiza koja je objedinila podatke o erlotinibu prikupljene od 204 bolesnika s rakom gušterače koji su primali erlotinib i gemcitabin.
English: Cut-off date: April 2012
Croatian: Podaci do: travanj 2012.
English: Rash***
Croatian: Proljev**